Justin Walsh
Stock Analyst at Jones Trading
(3.05)
# 1,701
Out of 5,099 analysts
37
Total ratings
40%
Success rate
15.66%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $261.58 | -68.27% | 1 | Sep 18, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $109 → $84 | $60.82 | +38.11% | 10 | Sep 16, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.28 | +971.43% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $3.31 | +262.54% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $6.68 | +349.10% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $78.22 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $3.21 | +242.68% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $14.28 | +26.05% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $28.67 | +46.49% | 1 | Oct 18, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $2.55 | +762.75% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.23 | +121.45% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.61 | +333.84% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.66 | +509.20% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.33 | +361.89% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $10.33 | +3,385.00% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.10 | +39,900.00% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.67 | +11,057.39% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $50.20 | -60.16% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.30 | +15,284.62% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.25 | +90.48% | 1 | Jan 19, 2022 |
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $261.58
Upside: -68.27%
Lantheus Holdings
Sep 16, 2025
Maintains: Buy
Price Target: $109 → $84
Current: $60.82
Upside: +38.11%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.28
Upside: +971.43%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $3.31
Upside: +262.54%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $6.68
Upside: +349.10%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $78.22
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $3.21
Upside: +242.68%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $14.28
Upside: +26.05%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $28.67
Upside: +46.49%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $2.55
Upside: +762.75%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $7.23
Upside: +121.45%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.61
Upside: +333.84%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.66
Upside: +509.20%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $4.33
Upside: +361.89%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $10.33
Upside: +3,385.00%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.10
Upside: +39,900.00%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.67
Upside: +11,057.39%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $50.20
Upside: -60.16%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.30
Upside: +15,284.62%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $5.25
Upside: +90.48%